FDA Warns Danish Drugmaker for Testing Failures By Sam | March 24, 2020 The FDA issued a warning letter to DermaPharm for serious GMP violations including inadequate testing of raw materials and finished products. Source: Devices & Diagnostics Letter Posted in Devices & Diagnostics Letter